The global diabetic nephropathy market is anticipated to grow at a considerable CAGR of 5.3% during the forecast period (2021-2027). As per CDC, diabetes is the major reason for end-stage renal disease (ESRD). Around 26 million people in the US had diabetes in 2011, and amongst them, more than 200,000 people had end-stage renal disease due to diabetes. At this stage, a kidney transplant is the only treatment that can be implemented. However, medications, kidney dialysis, and acupuncture are other possible treatments. Medication is the primary treatment given to the patients. Diuretics, angiotensin-converting enzyme inhibitors, antioxidant inflammation modulator, angiotensin receptor blockers, renin inhibitors, calcium channel blockers, monocyte chemoattractant proteins inhibitor, and G protein-coupled receptors are the prominent medications given to patients of diabetic nephropathy.
(Get 15% Discount on Buying this Report)
Get Report Sample Copy @ https://www.omrglobal.com/request-sample/diabetic-nephropathy-market
According to the International Journal of Advances in Medicine, around 79.4 million people will have diabetes in 2030, and by the time they get diagnosed they have been affected with some other nephropathy disease. This had given a clear vision of the growing diabetic nephropathy market in the future.
A Full Report of Global Diabetic Nephropathy Market is Available at: https://www.omrglobal.com/industry-reports/diabetic-nephropathy-market
Global Diabetic Nephropathy Market Report Segment
By Indication
- Diabetes Type-1
- Diabetes Type-2
By Diagnosis
- Urine Test
- Imaging Test
- Blood Test
- Renal Function Test
- Renal Biopsy
By Treatment
- Medication
- Kidney Dialysis
- Kidney Transplant
- Acupuncture
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
